Exit Strategies for SME Life Science Companies in the EU
When funding life science companies, investors need realistic expectations on how to recover their investment and, potentially, returns on their investment. A number of options exist, commonly c...
Read moreIncentives, IP and Smaller Companies: The Story of uniQure
Download the Case Story in PDF format here uniQure, based in Amsterdam in the Netherlands and Lexington, Massachusetts, USA, is developing curative gene therapies for patients with severe geneti...
Read moreKPMG Report: Site Selection for Life Sciences Companies in Europe 2018
EBE supports the 2018 version of the KPMG report on site selection for life science companies in Europe, developed in collaboration with Venture Valuation. Each company seeking to establish European...
Read moreEuropean Investment Bank Report: “Financing the next wave of medical breakthroughs – What works and what needs fixing?”
EBE was proud to support the launch of the European Investment Bank's report "Access-to-finance conditions for Life Sciences R&D" at BioEurope Spring. This reports identifies a number of necessary...
Read moreIncentives for Innovation. Incentivising Research in Areas of High Unmet Medical Need: Lilly’s Alzheimer’s Quest
With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems....
Read morePresentations and Conference Report from the 6th EBE Annual Conference on ATMPs – 5 December 2017, London
UPDATE 12 February 2018: Conference Report now available here The remarkable opportunities that cell and gene therapies can offer, but also the seemingly increasing number of obstacles to their wi...
Read moreIncentives, IP and smaller companies: the story of Lysogene
Download the Case Story in PDF format here How Lysogene contributes to improving health outcomes Founded in France in 2009, and employing 18 staff at the end of 2017, Lysogene spec...
Read moreIncentives for Innovation: the story of Gilenya by Novartis
With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcar...
Read moreIncentives, IP and smaller companies – the story of Transgene
Download the Case Story in PDF format here How Transgene wants to change patients’ lives by improving health outcomes Transgene S.A., founded in December 1979, and part of the Fr...
Read moreIncentives, IP and smaller companies – the story of Vaxeal
Download the Case Story in PDF format here Vaxeal Holding SA is headquartered in Vevey, Switzerland, with operations in Evry and Paris, France. The company was created in 2009. It de...
Read more